Celltrion's ADC Anticancer Drug 'CT-P70' Granted Fast Track Designation by U.S. FDA
Establishing a Rapid Review System for Future Pipeline Candidates
Celltrion announced on December 4 that its antibody-drug conjugate (ADC) based anticancer drug candidate, CT-P70, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
The FDA’s Fast Track program is designed for serious conditions where existing treatments are insufficiently effective, allowing for expedited communication between the developer and the FDA throughout the clinical development process. With Fast Track designation, developers can benefit from: ▲ continuous communication channels with the FDA ▲ early consultation on clinical trial design and development strategy ▲ increased possibility of priority review and accelerated approval ▲ rolling review, among other advantages.
CT-P70 is a new treatment option for patients with metastatic non-squamous non-small cell lung cancer who express cMET (cellular growth factor receptor) and have previously undergone systemic therapy. In March, Celltrion received FDA approval for its Investigational New Drug (IND) application, and is currently administering the drug to patients in a Phase 1 clinical trial.
The FDA is reported to have granted Fast Track designation after comprehensively evaluating the fact that the target patient group is at high risk with limited treatment options using existing methods, as well as the potential shown by the initial development data of CT-P70.
With this Fast Track designation, Celltrion plans to establish a “rapid development system” by securing expedited communication channels with the FDA, with the aim of obtaining Fast Track designation for additional pipeline candidates in the future. Celltrion also plans to sequentially apply for Fast Track designation for its subsequent ADC and multi-antibody based pipeline candidates, including CT-P71, CT-P72, and CT-P73.
Meanwhile, by the end of this year, Celltrion aims to advance a total of four drug candidates, including CT-P70, into the clinical stage, and to expand its new drug pipeline to 20 candidates?including more than 10 in clinical development?by 2027.
To this end, Celltrion is securing platform technologies in a wide range of areas, such as ADCs and multi-antibodies, through collaboration with various companies. The strategy is to strengthen technological competitiveness by ensuring high scalability across antibody-chemical conjugation methods and formulation types. In addition to its existing platforms, the company is also enhancing its platform technologies to achieve higher therapeutic indices by improving efficacy and safety, pursuing both in-house development and expanded collaboration with multiple domestic and international partners.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion representative stated, “The Fast Track designation for CT-P70 is official confirmation from the FDA of Celltrion’s potential to address unmet medical needs with new therapies. Building on this designation, we plan to continue applying for Fast Track status for other ADC and multi-antibody drug candidates under development, and ultimately accelerate development to provide new treatment options to patients more quickly.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.